✦ LIBER ✦

Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon α in the treatment of metastatic renal cell carcinoma: a pilot study

✍ Scribed by Jörg Westermann; Gernot Reich; Joachim Kopp; Ulrike Haus; Bernd Dörken; Antonio Pezzutto

Publisher: Springer-Verlag
Year: 2001
Tongue: English
Weight: 143 KB
Volume: 49
Category: Article
ISSN: 0340-7004
DOI: 10.1007/s002620000159

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bacillus Calmette-Guérin plus interleuki

Bacillus Calmette-Guérin plus interleukin-2 and/or granulocyte/macrophage-colony-stimulating factor enhances immunocompetent cell production of interferon-γ, which inhibits B16F10 melanoma cell growth in vitro

✍ Toshihiro Fujimoto; Michael A. O’Donnell; Akos Szilvasi; H. Yang; R. B. Duda 📂 Article 📅 1996 🏛 Springer-Verlag 🌐 English ⚖ 228 KB

Dose escalation study of carboplatin wit

Dose escalation study of carboplatin with fixed-dose etoposide plus granulocyte-colony stimulating factor in patients with small cell lung carcinoma: A study of the lung cancer study group of west Japan

✍ Nobuyuki Katakami; Minoru Takada; Shunichi Negoro; Katsuyasu Ota; Jiro Fujita; K 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 738 KB

## BACKGROUND. We performed a Phase 1-11 trial to determine the maximum tolerated dose of carboplatin (CBDCA) with a fixed dose of VP-16 and granulocyte-colony stimulating factor (G-CSF) in small cell lung cancer (SCLC) patients. ## METHODS. Treatment consisted of a starting dose of CBDCA, 400

Phase II study of cisplatin as a 5-day c

Phase II study of cisplatin as a 5-day continuous infusion with vindesine plus recombinant human granulocyte-colony-stimulating factor in the treatment of advanced non-small-cell lung cancer

✍ Yoshikuni Saito; Kiyoshi Mori; Keigo Tominaga; Kouhei Yokoi; Naoto Miyazawa 📂 Article 📅 1992 🏛 Springer 🌐 English ⚖ 500 KB

Subcutaneous interleukin-2 and interfero

Subcutaneous interleukin-2 and interferon α in the treatment of patients with metastatic renal cell carcinoma—Less efficacy compared with intravenous interleukin-2 and interferon α : Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie

✍ Alain Ravaud; Rémy Delva; Fréderic Gomez; Christine Chevreau; Jean-Yves Douillar 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 1 views

## Background: The main objective of this trial was to evaluate the combination of subcutaneous (sc) interleukin-2 (il-2) with interferon alpha-2a (ifn-alpha) in the treatment of patients with metastatic renal cell carcinoma (mrcc) compared with a previous trial that used continuous-infusion il-2 a

Interleukin-2, interferon-α, 5-fluoroura

Interleukin-2, interferon-α, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma : A prospective Phase II study: The experience of Rambam and Lin Medical Centers 1996-2000

✍ Eliahu Gez; Raphael Rubinov; Diana Gaitini; Shimon Meretyk; Lael-Anson Best; Ofe 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

## Abstract ## BACKGROUND The current study evaluated the efficacy and toxicity of interleukin‐2 (IL‐2), interferon‐α (IFN‐α), 5‐fluorouracil (5‐FU), and vinblastine (VBL) in the treatment of metastatic renal cell carcinoma (MRCC). ## METHODS Sixty‐two MRCC patients, median age 63 years, receive